Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883211 | 1.00 | CA2 (0.35) | CA2HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL3020689 | 1.00 | CA2 (0.35) | CA2HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL8875465 | 0.84 | CA2 (0.34) | CA2HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL1030224 | 0.84 | HCRTR2 (0.39) | CA2HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL2038232 | 0.84 | HCRTR2 (0.39) | CA2HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL1030223 | 0.84 | HCRTR2 (0.39) | CA2HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL2936811 | 0.82 | HCRTR2 (0.38) | CA2HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL3920999 | 0.82 | GAA (0.38) | CA2HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL2936815 | 0.82 | HCRTR2 (0.38) | CA2HCRTR2HCRTR1TMEM97SIGMAR1 | |
| Acetic Acid SCHEMBL21617326 | 0.82 | HCRTR2 (0.38) | CA2HCRTR2HCRTR1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235380-A1 | MACROLIDES FOR TREATING GENETIC DISEASES | ZIKANI THERAPEUTICS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11634449-B2 | Macrolides and methods of their preparation and use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230109357-A1 | 14-MEMBERED KETOLIDES AND METHODS OF THEIR PREPARATION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4095146-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | President And Fellows Of Harvard College (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20220332747-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-10-20 | — | — | US | disclosed |
| US-11466046-B2 | 14-membered ketolides and methods of their preparation and use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3519411-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2022-06-22 | — | — | EP | disclosed |
| EP-2988597-B1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | HARVARD COLLEGE (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-3883945-A1 | C11-CYCLIC SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10913764-B2 | Macrolides and methods of their preparation and use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-02-09 | — | — | US | disclosed |
| EP-2315754-A1 | PYRIMIDYL SULFONAMINDE DERIVATIVE AND ITS USE FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2011-05-04 | — | — | EP | disclosed |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010007427-A1 | PYRIMIDYL SULFONAMINDE DERIVATIVE AND ITS USE FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007427-A1 | PYRIMIDYL SULFONAMINDE DERIVATIVE AND ITS USE FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016275-A1 | NOVEL COMPOUND 395 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016275-A1 | NOVEL COMPOUND 395 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009108838-A1 | BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-03 | — | — | WO | disclosed |
| US-7176229-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466046-B2 | 14-membered ketolides and methods of their preparation and use | CYP51A1, KHK, HSD17B7 | CA2 3156/4885HCRTR2 3389/4885HCRTR1 3303/4885 |
| US-20220332747-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | CYP11B2, ERG28, DHCR7 | CA2 4851/4885HCRTR2 3027/4885HCRTR1 3244/4885 |
| US-20100016275-A1 | NOVEL COMPOUND 395 | CCL5, CCL2, CCL11 | CA2 4510/4885HCRTR2 2344/4885HCRTR1 1886/4885 |
| US-11634449-B2 | Macrolides and methods of their preparation and use | CYP11B2, ERG28, DHCR7 | CA2 4851/4885HCRTR2 3027/4885HCRTR1 3244/4885 |
| US-10913764-B2 | Macrolides and methods of their preparation and use | CYP11B2, ERG28, DHCR7 | CA2 4851/4885HCRTR2 3027/4885HCRTR1 3244/4885 |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | BRAF, RAF1, ARAF | CA2 3238/4885HCRTR2 4525/4885HCRTR1 4280/4885 |
| US-20230109357-A1 | 14-MEMBERED KETOLIDES AND METHODS OF THEIR PREPARATION AND USE | CYP51A1, KHK, HSD17B7 | CA2 3156/4885HCRTR2 3389/4885HCRTR1 3303/4885 |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | CA2 4139/4885HCRTR2 4664/4885HCRTR1 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.